NasdaqGS - Delayed Quote USD

2seventy bio, Inc. (TSVT)

4.6300 -0.0200 (-0.43%)
At close: April 23 at 4:00 PM EDT
4.5300 -0.10 (-2.16%)
After hours: April 23 at 7:29 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
100,387.0000
100,387.0000
91,496.0000
54,522.0000
248,122.0000
Cost of Revenue
16,918.0000
16,918.0000
26,219.0000
21,908.0000
5,396.0000
Gross Profit
83,469.0000
83,469.0000
65,277.0000
32,614.0000
242,726.0000
Operating Expense
300,172.0000
300,172.0000
328,185.0000
346,123.0000
387,364.0000
Operating Income
-216,703.0000
-216,703.0000
-262,908.0000
-313,509.0000
-144,638.0000
Net Non Operating Interest Income Expense
12,413.0000
12,413.0000
2,932.0000
88.0000
--
Other Income Expense
-13,280.0000
-13,280.0000
5,823.0000
21,208.0000
24,524.0000
Pretax Income
-217,570.0000
-217,570.0000
-254,153.0000
-292,213.0000
-120,114.0000
Net Income Common Stockholders
-217,570.0000
-217,570.0000
-254,153.0000
-292,213.0000
-120,114.0000
Diluted NI Available to Com Stockholders
-217,570.0000
-217,570.0000
-254,153.0000
-292,213.0000
-120,114.0000
Basic EPS
-3.77
-4.42
-7.13
-12.44
-5.16
Diluted EPS
-3.77
-4.42
-7.13
-12.44
-5.16
Basic Average Shares
46,102.5000
49,276.0000
35,637.0000
23,499.0000
23,287.4570
Diluted Average Shares
46,102.5000
49,276.0000
35,637.0000
23,499.0000
23,287.4570
Total Operating Income as Reported
-237,608.0000
-237,608.0000
-263,140.0000
-313,948.0000
-138,170.0000
Total Expenses
317,090.0000
317,090.0000
354,404.0000
368,031.0000
392,760.0000
Net Income from Continuing & Discontinued Operation
-217,570.0000
-217,570.0000
-254,153.0000
-292,213.0000
-120,114.0000
Normalized Income
-196,665.0000
-196,665.0000
-253,921.0000
-291,774.0000
-126,582.0000
Interest Income
12,413.0000
12,413.0000
2,932.0000
88.0000
--
Net Interest Income
12,413.0000
12,413.0000
2,932.0000
88.0000
--
EBIT
-216,703.0000
-216,703.0000
-262,908.0000
-313,509.0000
-144,638.0000
EBITDA
-206,418.0000
-206,418.0000
-251,375.0000
-297,159.0000
-131,450.0000
Reconciled Cost of Revenue
16,918.0000
16,918.0000
26,219.0000
21,908.0000
5,396.0000
Reconciled Depreciation
10,285.0000
10,285.0000
11,533.0000
16,350.0000
13,188.0000
Net Income from Continuing Operation Net Minority Interest
-217,570.0000
-217,570.0000
-254,153.0000
-292,213.0000
-120,114.0000
Total Unusual Items Excluding Goodwill
-20,905.0000
-20,905.0000
-232.0000
-439.0000
6,468.0000
Total Unusual Items
-20,905.0000
-20,905.0000
-232.0000
-439.0000
6,468.0000
Normalized EBITDA
-185,513.0000
-185,513.0000
-251,143.0000
-296,720.0000
-137,918.0000
12/31/2020 - 11/3/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BLUE bluebird bio, Inc.
0.9706
+1.78%
 
KPTI Karyopharm Therapeutics Inc.
1.0900
-3.54%
 
CHRS Coherus BioSciences, Inc.
2.1800
0.00%
 
SGMT Sagimet Biosciences Inc.
4.2800
+6.20%
 
ADAP Adaptimmune Therapeutics plc
1.1400
+12.87%
 
ADCT ADC Therapeutics SA
4.9700
+6.20%
 
YMAB Y-mAbs Therapeutics, Inc.
15.34
+1.19%
 
XFOR X4 Pharmaceuticals, Inc.
1.2300
-9.56%
 
LEGN Legend Biotech Corporation
47.45
+0.83%
 
PSTX Poseida Therapeutics, Inc.
2.1600
+0.23%